Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON (dpa-AFX) - Adicet Bio, Inc. (ACET) reported a second quarter net loss attributable to common shareholders of $22.5 million, or a net loss of $0.56 per share, as compared to a net loss
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcom...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, today announced that...
/PRNewswire/ -- The global cellular immunotherapy market size is expected to reach USD 37.97 billion by 2030, according to a new report by Grand View Research,...
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on June 30, 2022 (the “Grant Date”) under Adicet’s 2022 Inducement Pl...